Bausch + Lomb Is Beating Estimates by 62%. The Stock Barely Moved.

There is a particular kind of investment opportunity that shows up when a company’s operating results and its stock price are running on separate tracks. Bausch + Lomb is one of those right now.

In late October, BLCO reported third-quarter adjusted earnings of $0.34 a share against a Wall Street consensus of $0.21. That beat came in at nearly 62%. Revenue reached $1.375 billion, ahead of forecasts. Adjusted EBITDA surged 34% to $325 million, with margin expanding 460 basis points to 23.6%, and free cash flow hit $178 million, its strongest since the 2022 IPO. And yet, as of mid-November, the stock is trading around $20. That is barely above where it sat a year ago.

The disconnect matters because the Q3 results were not an accident. They were the fourth consecutive quarter in which Bausch + Lomb met or exceeded the targets it laid out at its November 2025 Investor Day. Management said at the outset that adjusted EBITDA would grow at nearly three times the rate of revenue. That is exactly what has happened: adjusted EBITDA growing at a rate of nearly 3x that of revenue.

A lower fixed cost structure has driven 150 basis points of year-to-date improvement in operating leverage, and net leverage has fallen from 5.7x a year ago to 4.1x at the end of Q3. The balance sheet is healing faster than expected.

Guidance has been raised three times this year. The company now targets full-year revenue of $5.45 billion to $5.55 billion, EBITDA of $1.09 billion to $1.14 billion, and adjusted EBITDA margin of about 20.3% at the midpoint.

Analysts are catching up. HC Wainwright raised its Q4 2026 EPS estimate to $0.34 from $0.28 and bumped its fiscal 2027 EPS estimate to $1.05 from $0.89. Zacks added BLCO to its Rank 1 Strong Buy list and highlighted it as a potential long-term value stock.

The valuation case rests on a PEG ratio well below 1, reflecting earnings growth that substantially outruns the price investors are paying for it. That low-beta profile (around 0.52) means the stock has not moved violently in either direction, which is both why it stays cheap and why patient investors can accumulate without chasing.

The risk is real: net leverage at 4.1x leaves limited cushion if revenue growth decelerates, and a leadership transition following the departure of CEO Brent Saunders adds execution uncertainty heading into 2027. Investors should track whether interim CEO Tom Appio sustains the operational discipline that produced these results.

The wealth takeaway is straightforward. When a healthcare company beats earnings by 62%, raises guidance three times in a row, and its stock price barely responds, the market is pricing in doubt the fundamentals have not earned. That gap rarely stays open indefinitely.